Vir Biotechnology (VIR) Receivables - Accured (2020 - 2024)

Vir Biotechnology's Revenue - Other history runs 6 years deep, the most recent figure standing at $1.9 million for Q1 2023.

• In Q1 2023, Revenue - Other fell 26.92% year-over-year to $1.9 million; the TTM figure through Mar 2023 stood at $8.0 million (down 15.09% YoY), while the FY2022 annual figure was $8.6 million, up 4.88% from the prior year.
• Revenue - Other came in at $1.9 million for Q1 2023 at Vir Biotechnology, up from $896000.0 in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $5.7 million in Q1 2024 to a low of $600000.0 in Q2 2021.
• A 5-year average of $2.1 million and a median of $1.8 million in 2022 frame the typical range for Receivables - Accured.
• Across the five-year window, Revenue - Other soared 553.88% in 2020 and sank 88.53% in 2021, its largest moves.
• Vir Biotechnology's Revenue - Other stood at $1.2 million in 2019, then rose by 19.42% to $1.4 million in 2020, then surged by 98.46% to $2.8 million in 2021, then slumped by 68.5% to $896000.0 in 2022, then soared by 112.05% to $1.9 million in 2023.
• According to Business Quant data, Revenue - Other over the past three periods registered $1.9 million, $896000.0, and $3.1 million for Q1 2023, Q4 2022, and Q3 2022 respectively.

Peer Comparison